Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.

[1]  G. Emons,et al.  GnRH antagonists in the treatment of gynecological and breast cancers. , 2003, Endocrine-related cancer.

[2]  G. Saggese,et al.  Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results , 2002, Hormone Research in Paediatrics.

[3]  L. Kiesel,et al.  Clinical use of GnRH analogues , 2002, Clinical endocrinology.

[4]  W. Sippell,et al.  Treatment of central precocious puberty. , 2002, Best practice & research. Clinical endocrinology & metabolism.

[5]  G. Saggese,et al.  The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: Results from a controlled study , 2001 .

[6]  N. Skakkebaek,et al.  Hormonal Changes During GnRH Analogue Therapy in Children with Central Precocious Puberty , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[7]  G. Saggese,et al.  Is There a Place for Combined Therapy with GnRH Agonist Plus Growth Hormone in Improving Final Height in Short Statured Children? , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[8]  M. Savage,et al.  Diagnosis and Treatment of Growth Hormone Deficiency in Children and Adolescents: Towards a Consensus , 1998, Hormone Research in Paediatrics.

[9]  B. Carr,et al.  The effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women. , 1995, Fertility and sterility.

[10]  M. Frydman,et al.  Hyperprolactinemia after treatment of long-acting gonadotropin-releasing hormone analogue Decapeptyl in girls with central precocious puberty. , 1995, Fertility and sterility.

[11]  E. Mcgee,et al.  The effect of gonadotropin-releasing hormone agonists on adrenocorticotropin and cortisol secretion in adult premenopausal women. , 1993, The Journal of clinical endocrinology and metabolism.

[12]  D. Meldrum,et al.  Pituitary function before, during, and after chronic gonadotropin-releasing hormone agonist therapy. , 1992, Fertility and sterility.

[13]  C. Sklar,et al.  Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion. , 1991, The Journal of clinical endocrinology and metabolism.

[14]  R. Jansen,et al.  A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin‐releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol , 1991, The Australian & New Zealand journal of obstetrics & gynaecology.

[15]  L. Mettler,et al.  Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis. , 1991, Human reproduction.

[16]  A. Lindner,et al.  Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. , 1991, European urology.

[17]  L. De Cecco,et al.  Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results. , 1990, Fertility and sterility.

[18]  I. Bukovsky,et al.  D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas. , 1989, Fertility and sterility.

[19]  Z. Braf,et al.  The role of increased prolactin levels under gnrh analogue treatment in advanced prostatic carcinoma , 1988, Cancer.

[20]  H. Judd,et al.  Treatment of Endometriosis With a Long‐Acting Gonadotropin‐Releasing Hormone Agonist , 1987, Obstetrics and gynecology.

[21]  D. Herbert,et al.  Effect of synthetic luteinizing hormone releasing hormone on prolactin secretion from clonal pituitary cells. , 1977, Biochemical and biophysical research communications.